Planned Studies

  • Evaluate the prevalence and clinical implications of comorbid nasal and bronchial hyper responsiveness in patients managed in a range of settings (primary care, specialist/secondary care, pharmacy)
  • Evaluate the true diagnosed and undiagnosed burden of obstructive sleep apnea
  • Characterisation of interstitial lung disease (ILD) diagnostic practice around the world and implications on diagnostic agreement and access to licensed therapies
  • Implications of steroid tailoring on treatment outcomes in patients with COPD managed in routine care
  • Utilise routine care data to identify the optimum duration of antibiotics for respiratory infections
  • Evaluate the implications of single versus multiple device use on implementation of triple therapy in eligible patients with COPD managed in routine care
  • Device switching (e.g. from ICS/LABA DPI to pMDI)(s) to FP/FOR pMDIs (Transfform)
  • Real-world effectiveness of allergen immunotherapy
  • Development of a Longitudinal Asthma Treatment Step Algorithm and Association with Asthma Outcomes
  • Investigate bronchiolitis in early childhood as a predictor of future and asthma
  • Item reduce the EXACT (Exacerbations of Chronic Pulmonary Disease Tool) Questionnaire for improved exacerbation risk prediction (clinical use and self-(tele) monitoring)
  • Characterise the natural history of IPF vs non-IPF ILD in terms of FVC lung function decline
  • Comparative effectiveness of triple therapy versus guideline recommended dual therapy (ICS/LABA and LAMA/LABA) alternatives in patients with COPDImplications of ICS particle size on the management of routine care patients with a mixed asthma-COPD phenotype
  • Implications of ICS particle size on the management of respiratory patients with comorbid GERD
  • Evaluation of the impact of patient age on inhaled medication implementation (drug administration) errors and implications for treatment outcomes 
  • Utilise pharmacy dispensing data to validate primary care prescribing estimates of medication adherence behaviours
  • Develop tools to support real-life research involving patients with a mixed asthma-COPD phenotype
  • Clinical and Cost implications of OLDOSA (comorbid obstructive sleep apnea in patients with obstructive lung disease) 
  • Quantify indirect costs of treatment in respiratory and allergic diseases
  • Quantify clinical implications of oral steroid exposure in patients with respiratory and allergic diseases
  • Evaluate the burden of allergic disease study from multi-stakeholder (primary care, secondary care, pharmacy) perspectives
  • Provide recommendations and tools to help inform the design and quality appraisal of databases for observational research in respiratory and allergic airways disease
  • Identify and prioirtise multi-stakeholder end-user needs for TBS in respiratory and allergic airway disease
  • Guidance to standardise the development of TBS with utility for respiratory and allergic airway diseases
  • Systematic review of behavioural change theory in the context of TBS for respiratory and allergic airways disease